Competing interests
M.C.G.: Honoraria: MSD Oncology, AstraZeneca/MedImmune, GSK, Takeda, Roche, Bristol-Myers Squibb, Daiichi Sankyo/AstraZeneca, Regeneron, Pfizer, Blueprint Medicines, Novartis, Sanofi/Aventis, Medscape, Oncohost, Revolution Medicines. Consulting or Advisory Role: Bristol-Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Sanofi, Celgene, Daiichi Sankyo, Pfizer, Seagen, Lilly, GSK, Bayer, Blueprint Medicines, Janssen, Regeneron, Bayer, AbbVie, Mirati Therapeutics, Merck, Boehringer Ingelheim, Blueprint Medicines, Avion, Gilead Sciences. Speakers’ Bureau: AstraZeneca, MSD Oncology, Merck, Mirati Therapeutics, Daiichi Sankyo/AstraZeneca; Research Funding (Inst): Bristol-Myers Squibb, MSD, Roche/Genentech, AstraZeneca/MedImmune, AstraZeneca, Pfizer, GSK, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceuticals, Blueprint Medicines, Lilly, Ipsen, Janssen, Exelixis, MedImmune, Sanofi, Pfizer, Amgen. Travel, Accommodations, Expenses: Pfizer, Roche, AstraZeneca, Merck. Uncompensated Relationships: Merck. M-J.A.: Honoraria: AstraZeneca, Lilly, MSD, Takeda, Amgen, Merck Serono, Yuhan, Daiichi Sankyo/AstraZeneca. Consulting or Advisory Role: AstraZeneca, Lilly, MSD, Takeda, Alpha Pharmaceutical, Amgen, Merck Serono, Pfizer, Yuhan, Arcus Ventures, Daiichi Sankyo/AstraZeneca. Research Funding: Yuhan. L.P-A.: Leadership: Altum Sequencing, Stab Therapeutics. Stock and Other Ownership Interests: Altum Sequencing, Stab Therapeutics. Honoraria: Roche/Genentech, Lilly, Pfizer, Bristol-Myers Squibb, MSD, AstraZeneca, Merck Serono, PharmaMar, Novartis, Amgen, Sanofi, Bayer, Takeda, Mirati Therapeutics, Daiichi Sankyo, BeiGene, GSK, Janssen, Medscape, Regeneron, Boehringer Ingelheim. Consulting or Advisory Role: Lilly, MSD, Roche, PharmaMar, Merck, AstraZeneca, Novartis, Amgen, Pfizer, Sanofi, Bayer, Bristol-Myers Squibb, Mirati Therapeutics, GSK, Janssen, Takeda, Regeneron, AbbVie. Speakers’ Bureau: MSD Oncology, Bristol-Myers Squibb, Roche/Genentech, Pfizer, Lilly, AstraZeneca, Merck Serono. Research Funding (Institution): Bristol-Myers Squibb, AstraZeneca, PharmaMar, MSD, Pfizer. Other Relationships: Novartis, Ipsen, Pfizer, Servier, Sanofi, Roche, Amgen, Merck, Roche. A.L.: Employment: Boston Scientific; Stock and Other Ownership Interests: Boston Scientific; Consulting or Advisory Role: AstraZeneca, Leica Biosystems, Bristol-Myers Squibb, Novocure, Pfizer, Jazz Pharmaceuticals, MorphoSys, Lilly, Oncocyte, Novartis, Sanofi/Regeneron, Janssen Oncology, Sanofi, G1 Therapeutics, Molecular Axiom, Amgen, Daiichi Sankyo Nordics, Bayer, IQVIA. Research Funding: Daiichi Sankyo, AstraZeneca, Calithera Biosciences, Dracen, WindMIL, Duality Biologics, eFFECTOR Therapeutics. Patents, Royalties, Other Intellectual Property: Pending Patents U.S. Provisional Patent Application No. 63/527,899. M.L.J.: Consulting or Advisory Role: AbbVie (Inst), Alentis Therapeutics (Inst), Amgen (Inst), Arcus Biosciences (Inst), ArriVent Biopharma (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), D3 Bio (Inst), Daiichi Sankyo (Inst), Fate Therapeutics (Inst), Genentech/Roche (Inst), Genmab (Inst), Genocea Biosciences (Inst), Gilead Sciences (Inst), GSK (Inst), Gritstone Bio (Inst), Hookipa Biotech (Inst), Immunocore (Inst), Janssen Oncology (Inst), Jazz Pharmaceuticals (Inst), Lilly (Inst), Merck (Inst), Mirati Therapeutics (Inst), Molecular Axiom (Inst), Normunity (Inst), Novartis (Inst), Novocure (Inst), Pfizer (Inst), Pyramid Biosciences (Inst), Revolution Medicines (Inst), Sanofi (Inst), SeaGen (Inst), Synthekine (Inst), Takeda (Inst), VBL Therapeutics (Inst). Research Funding: AbbVie (Inst), Adaptimmune (Inst), Amgen (Inst), Apexigen (Inst), Arcus Biosciences (Inst), Array BioPharma (Inst), ArriVent Biopharma (Inst), Artios (Inst), AstraZeneca (Inst), Atreca (Inst), Bayer (Inst), BeiGene (Inst), BerGenBio (Inst), BioAtla (Inst), Black Diamond Therapeutics (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Carisma Therapeutics (Inst), Checkpoint Therapeutics (Inst), City of Hope (Inst), Corvus Pharmaceuticals (Inst), Curis (Inst); CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dracen (Inst), Dynavax Technologies (Inst), Elicio Therapeutics (Inst), EMD Serono (Inst), EQRx (Inst), Erasca, Inc (Inst), Exelixis (Inst), Fate Therapeutics (Inst), Genentech/Roche (Inst), Genmab (Inst), Genocea Biosciences (Inst), GSK (Inst), Gritstone Bio (Inst), Guardant Health (Inst), Harpoon (Inst), Helsinn Healthcare (Inst), Hengrui Pharmaceutical (Inst), Hutchison MediPharma (Inst), IDEAYA Biosciences (Inst), IGM Biosciences (Inst), Immunitas (Inst), Immunocore (Inst), Incyte (Inst), Janssen (Inst), Jounce Therapeutics (Inst), Kadmon (Inst), Kartos Therapeutics (Inst), Lilly (Inst); LockBody Therapeutics (Inst), Loxo (Inst), Lycera (Inst), Memorial Sloan Kettering Cancer Center (Inst), Merck (Inst), Merus (Inst), Mirati Therapeutics (Inst), Mythic Therapeutics (Inst), NeoImmuneTech (Inst), Neovia Oncology (Inst), Novartis (Inst), Numab (Inst), Nuvalent, Inc. (Inst), OncoMed (Inst), Palleon Pharmaceuticals (Inst), Pfizer (Inst), PMV Pharma (Inst), Rain Therapeutics (Inst), RasCal (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Revolution Medicines (Inst), Ribon Therapeutics (Inst), Rubius Therapeutics (Inst), Sanofi (Inst), Seven and Eight Biopharmaceuticals (Inst), Shattuck Labs (Inst), Silicon Therapeutics (Inst), Stem CentRx (Inst), Syndax (Inst), Taiho Oncology (Inst), Takeda (Inst), Tarveda Therapeutics (Inst), TCR2 Therapeutics (Inst), Tempest Therapeutics (Inst), Tizona Therapeutics, Inc. (Inst), Tmunity Therapeutics, Inc. (Inst), Turning Point Therapeutics (Inst), University of Michigan (Inst), Vyriad (Inst), WindMIL (Inst), Y-mAbs Therapeutics (Inst). Travel, Accommodations, Expenses: AbbVie, AstraZeneca, Genentech, Incyte, Merck, Pfizer, Sanofi. M.P.: Consulting or Advisory Role: Lilly, Roche/Genentech, Pfizer, AstraZeneca, MSD, Bristol-Myers Squibb, Novartis, Amgen, Takeda, Sanofi, GSK, Janssen Oncology, Ipsen, Eisai, Novocure, Daiichi Sankyo, Gilead Sciences. Research Funding: Takeda (Inst). Travel, Accommodations, Expenses: AstraZeneca, Roche, Bristol-Myers Squibb, MSD, Pfizer, Takeda, Chugai Pharma. T.S.: Honoraria: Daiichi Sankyo, Chugai Pharma, Taiho Pharmaceutical. Consulting or Advisory Role: Takeda, Daiichi Sankyo, AbbVie, Chordia Therapeutics. Speakers’ Bureau: Chugai Pharma; Research Funding (Inst): Bristol-Myers Squibb, Takeda/Millennium, Daiichi Sankyo, 3D Medicines, SymBio Pharmaceuticals, Novartis, Lilly, Eisai, Incyte, Chordia Therapeutics, Astellas Pharma, Pfizer, AstraZeneca, AbbVie, Lilly. Travel, Accommodations, Expenses: Takeda. R.H.: Consulting or Advisory Role: Novartis, Daichii Sankyo, AbbVie, Sanofi, Lilly, Regeneron, Claim Therapeutics, AstraZeneca, Merck, Biohaven Pharmaceuticals. Research Funding (Institution): AbbVie, Novartis, Roche, Mirati Therapeutics, Exelixis, Corvus Pharmaceuticals, Daiichi Sankyo, Agios, Pfizer, Lilly, Turning Point Therapeutics, Erasca, Inc, Mythic Therapeutics. A.S.: Leadership: Next Oncology (Inst); Stock and Other Ownership Interests: Lilly. Honoraria: CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol-Myers Squibb, Bayer. Consulting or Advisory Role: Array BioPharma (Inst), Incyte, Amgen, Novartis, AstraZeneca/MedImmune (Inst), Mirati Therapeutics, Gritstone Bio, Jazz Pharmaceuticals, Merck (Inst), Bristol-Myers Squibb (Inst), Takeda, Janssen, Mersana, Blueprint Medicines (Inst), Gritstone Bio, Daiichi Sankyo/AstraZeneca, Regeneron, Lilly, Black Diamond Therapeutics, Sanofi. Research Funding: Roche (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Astellas Pharma (Inst), MedImmune (Inst), Novartis (Inst), Incyte (Inst), AbbVie (Inst), Ignyta (Inst), Takeda (Inst), Macrogenics (Inst), CytomX Therapeutics (Inst), LAM Therapeutics, Astex Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Loxo (Inst), Arch Therapeutics (Inst), Gritstone Bio (Inst), Plexxikon (Inst), Amgen (Inst), Loxo (Inst), Daiichi Sankyo (Inst), ADC Therapeutics (Inst), Janssen Oncology (Inst), Mirati Therapeutics (Inst), ADC Therapeutics (Inst), Rubius Therapeutics (Inst), Synthekine (Inst), Mersana (Inst), Blueprint Medicines (Inst), Regeneron, Alkermes (Inst), Revolution Medicines (Inst), Medikine (Inst), Black Diamond Therapeutics (Inst), BluPrint Oncology (Inst), Nalo Therapeutics (Inst), Scorpion Therapeutics (Inst), ArriVent Biopharma (Inst), Revolution Medicines (Inst). I.O.: Honoraria: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical. Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb Japan, Chugai Pharma, Daiichi Sankyo/UCB Japan, Lilly Japan, Ono Pharmaceutical, Pfizer. Research Funding: AbbVie (Inst), Amgen (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Chugai/Roche (Inst), Daiichi Sankyo/UCB Japan (Inst), Lilly (Inst), MSD Oncology (Inst), Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst). N.G.: Employment: AstraZeneca. Consulting or Advisory Role: Roche, Lilly, AstraZeneca, Novartis, Pfizer, Bristol-Myers Squibb, MSD, Takeda, Janssen, Sanofi, Amgen, Gilead Sciences, BeiGene, AbbVie, Daiichi Sankyo/AstraZeneca, LEO Pharma, Ipsen. Research Funding: Roche (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), MSD Avenir (Inst). Travel, Accommodations, Expenses: Roche, Janssen Oncology, Janssen Oncology. R. Cornelissen: Honoraria: Roche, Pfizer, Spectrum Pharmaceuticals, Bristol-Myers Squibb/Pfizer, MSD Oncology. Consulting or Advisory Role: MSD. E.P-T.: Consulting or Advisory Role: AstraZeneca, Sanofi Pasteur, Takeda, Daiichi Sankyo/AstraZeneca, Roche, Bristol-Myers Squibb Foundation, Janssen. Research Funding: AstraZeneca (Inst). Travel, Accommodations, Expenses: AstraZeneca, Takeda, Pfizer, Sanofi, Daiichi Sankyo/AstraZeneca. M.H.H.: Stock and Other Ownership Interests: GI Biome, GI cell. Honoraria: AstraZeneca; Merck; Roche. Consulting or Advisory Role: AstraZeneca, Merck, Roche, Yuhan. Research Funding: Yuhan. R.Z. and R. Chiaverelli are employees of Daiichi Sankyo. M. Schick, A.K., M.R., M. Sung, C.D., J.H., D.C., H.S. and J.S. are employees of AstraZeneca. J.S.: Honoraria: Pfizer. Consulting or Advisory Role: AstraZeneca, Medtronic, Daiichi Sankyo/UCB Japan, Sanofi, Boehringer Ingelheim, PharmaMar, Guardant Health, AbbVie, Gilead Sciences, Lilly, G1 Therapeutics. Research Funding: Amgen, Harpoon. Travel, Accommodations, Expenses: AstraZeneca.
